Table 3. Medically attended lower respiratory illness among MEDI-559 and placebo recipients.
| MA-LRI Term | Dose | Days Post Dosing | Virology | |
|---|---|---|---|---|
| ≤28 days post any dose | ||||
| MEDI-559 (n=6) | Wheezinga | 1 | 12 | No virus detected |
| Wheezing | 1 | 10 | RSV B | |
| Wheezing | 1 | 28 | No virus detected | |
| Bronchiolitisa | 2 | 2 | RSV A/Influenza A | |
| Bronchiolitis | 2 | 10 | No virus detected | |
| Croup | 3 | 2 | RSV A | |
| Placebo (n=1) | Wheezing | 3 | 14 | RSV B |
| >28 days post any dose | ||||
| MEDI-559 (n=6) | Bronchiolitisb | 1 | 29 | No virus detected |
| Wheezinga | 1 | 54 | RSV A/Influenza A | |
| Bronchiolitisb | 3 | 36 | Influenza B | |
| Bronchiolitis | 3 | 75 | No sample collected | |
| Bronchiolitis | 3 | 102 | Influenza B | |
| Wheezing | 3 | 126 | No virus detected | |
| Placebo (n=6) | Wheezingc | 1 | 30 | RSV B/Influenza B |
| Wheezing | 1 | 55 | No virus detected | |
| Bronchitisc | 3 | 35 | HMPV | |
| Croup | 3 | 59 | No virus detected | |
| Bronchiolitis | 3 | 77 | No sample collected | |
| Bronchiolitis | 3 | 153 | No sample collectedd | |
HMPV, human metapneumovirus; MA-LRI, medically attended lower respiratory illness; NW, nasal wash; RSV, respiratory syncytial virus
a
Subject had 3 MA-LRI events
b
Subject had 2 MA-LRI events
c
Subject had 2 MA-LRI events
d
RSV positive by outside clinical lab